tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AXSM Stock Latest News

Strategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics
RatingsStrategic Acquisition and Pipeline Expansion Drive Buy Rating for Axsome Therapeutics
20d ago
AXSM
Avenue Therapeutics announces Baergic Bio acquisition by Axsome
PremiumThe Fly
Avenue Therapeutics announces Baergic Bio acquisition by Axsome
27d ago
AZN
ATXI
Axsome enters agreement to obtain exclusive global rights to AZD7325
PremiumThe Fly
Axsome enters agreement to obtain exclusive global rights to AZD7325
27d ago
AZN
ATXI
Axsome Therapeutics price target raised to $202 from $200 at Mizuho
PremiumThe Fly
Axsome Therapeutics price target raised to $202 from $200 at Mizuho
27d ago
AXSM
Axsome Therapeutics management to meet with Truist
PremiumThe Fly
Axsome Therapeutics management to meet with Truist
28d ago
AXSM
Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges
PremiumCompany AnnouncementsAxsome Therapeutics’ Earnings Call Highlights Growth and Challenges
28d ago
AXSM
Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
Premium
The Fly
Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
29d ago
AXSM
Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
Premium
The Fly
Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
29d ago
AXSM
Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
PremiumThe Fly
Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley
29d ago
AXSM
Axsome Therapeutics price target raised to $178 from $176 at BofA
PremiumThe Fly
Axsome Therapeutics price target raised to $178 from $176 at BofA
29d ago
AXSM
Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
PremiumThe Fly
Axsome Therapeutics price target lowered to $157 from $163 at Wells Fargo
29d ago
AXSM
Axsome Therapeutics Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Axsome Therapeutics Reports Strong Q3 2025 Growth
29d ago
AXSM
Axsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
PremiumRatingsAxsome Therapeutics’ Strong Market Position and Growth Potential Highlighted by Impressive Auvelity Performance and Strategic Expansion
29d ago
AXSM
Axsome Therapeutics files automatic mixed securities shelf
Premium
The Fly
Axsome Therapeutics files automatic mixed securities shelf
29d ago
AXSM
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
Premium
Ratings
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
30d ago
AXSM
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating
PremiumRatings
Axsome Therapeutics: Strong Financial Performance and Strategic Advancements Justify Buy Rating
30d ago
AXSM
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025
PremiumCompany Announcements
Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025
30d ago
8K
AXSM
Axsome Therapeutics reports Q3 EPS (94c), consensus (90c)
PremiumThe Fly
Axsome Therapeutics reports Q3 EPS (94c), consensus (90c)
30d ago
AXSM
Is AXSM a Buy, Before Earnings?
PremiumPre-Earnings
Is AXSM a Buy, Before Earnings?
1M ago
AXSM
Axsome Therapeutics Advances Study on Solriamfetol for Binge Eating Disorder
PremiumCompany AnnouncementsAxsome Therapeutics Advances Study on Solriamfetol for Binge Eating Disorder
1M ago
AXSM
Axsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder
Premium
Company Announcements
Axsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder
1M ago
AXSM
Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention
Premium
Company Announcements
Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention
1M ago
AXSM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >